Biosafety evaluation of chitosan lactate/hyaluronate sponge

doi:10.3969/j.issn.2095-4344.1628

Abstract

Abstract:

BACKGROUND: Functional dressings have been widely used in clinical practice, but so far none of existing dressings can meet the clinical needs in terms of gas permeability, biocompatibility, comfort, and degradability.

OBJECTIVE: To systemically evaluate the biosafety properties of water-soluble chitosan lactate/hyaluronan sponge after modification.

METHODS: In the study, there were 10 male BALB/C mice of SPF grade (6-8 weeks old), 20 Sprague-Dawley rats of SPF grade (7 weeks old, both genders), and 3 male New Zealand white rabbits (8 weeks old), all provided by Dongguan Songshanhu Pearl Animal Technology Co., Ltd. The chitosan lactate/hyaluronan sponge was prepared for cytotoxicity test. A blank control group was set. According to the GB/T16886 biological evaluation system, the rabbits were subjected to composite sponge stimulation and sensitization and intradermal reaction tests from the perspective of biosafety, and then divided into non-polar extract group, polar extract group and negative control group. The inoculation site was observed within 72 hours. The mice were subjected to acute toxicity test, and divided into experimental group (extraction solution) and control group (pure saline), and their manifestations were observed for 72 hours. The rats were subjected to subchronic toxicity test, and then divided into experimental group (subcutaneous implantation of composite sponge) and control group (making a skin incision on the back followed by suturing). The changes in body weight of the rats were observed, blood samples from the rats were taken intravenously for blood routine analysis at 13 weeks after testing, and the rats were anesthetized and executed in the next day for gross observations of the heart, liver, spleen, kidney, brain, pancreas, thymus, stomach, and bladder.

RESULTS AND CONCLUSION: (1) The chemical structure of the modified composite sponge formed as expected. The cytotoxicity of the composite sponge was grade 1, which was not significantly different from the negative control group. (2) The skin irritation test showed no skin erythema and edema in the New Zealand white rabbits after being stimulated by the composite sponge, and the existing stimulation reactions were extremely mild. Almost no obvious sensitization reaction occurred. (3) No erythema and edema were captured in the intradermal reaction test, and intradermal reaction stimulation of the composite sponge was very weak. (4) In the acute toxicity test, no obvious toxicity symptoms such as hypocinesis, dyspnea and abdominal stimulation were observed in the mice. Furthermore, at the observational time point of 72 hours, no acute systemic toxicity occurred in the two groups. (5) In the subchronic toxicity test, no obvious difference was detected in the rat body mass between the experimental and control groups. The same conclusion was made in the hematology and organ coefficient tests. To conclude, the chitosan lactate/hyaluronate sponge has excellent biological properties and good biosafety, which can be applied for further clinical use.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Lactic Acid, Chitosan, Biocompatible Materials, Tissue Engineering

CLC Number:

R496

Cai Yuhui, Hu Kesu, Zhang Yi. Biosafety evaluation of chitosan lactate/hyaluronate sponge[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(10): 1558-1563.

Figures/Tables 6

References

[1] 赵琳,宋建星.创面敷料的研究现状与进展[J]. 中国组织工程研究与临床康复.2007,11(9):1724-1726.

[2] 孔易,徐瑞.壳聚糖/藻酸盐纳米膜在促进小鼠全层损伤皮肤创面愈合中的作用[J].第三军医大学学报.2015,37(21):2109-2114.

[3] 王竞男,罗嘉浩,杨立群,等.壳聚糖及其衍生物在药物载体方面的研究进展.转化医学杂志[J].2017,6(4):193-198.

[4] 刘琳娜,李学拥,赵聪颖,等.壳聚糖护创敷料用于深Ⅱ度烧伤创面的疗效和安全性:一项前瞻性、随机、单盲、阳性对照临床试验[J].中国组织工程研究,2017,21(14):2222-2226.

[5] 蔡少甫,余昌龙.壳聚糖联合纳米银医用抗菌敷料治疗老年Ⅱ度烧伤创面的疗效观察[J].中国社区医师,2016,32(6):78-79.

[6] Oana MD,Sangran KS,Mamoni D,et al. New antimicrobial chitosan derivatives for wound dressing Applications. Carbohydrate Polymers. 2016;141: 28-40.

[7] Chanphai P, Tajmir-Riahi HA. Chitosan nanoparticles conjugate with trypsin and trypsin inhibitor. Carbohydr Polym. 2016;144: 346–352.

[8] Ngo DH, Vo TS, Ngo DN, et al. Biological effects of chitosan and its derivatives. Food Hydrocolloids. 2015,51: 200–216.

[9] Pereira VA, Queiroz de Arruda IN, Stefani R. Active chitosan/PVA ?lms with anthocyanins from Brassica oleraceae(Red Cabbage) as time–temperature indicators for application in intelligent food packaging. Food Hydrocolloids. 2015;43:180–188.

[10] HaHaitang Xu, Lie Ma,Haifei Shi,et al. Chitosan–hyaluronic acid hybrid film as a novel wound dressing: in vitro and in vivo studies. Polym. Adv. Technol. 2007; 18: 869-875.

[11] Younes I,Rinaudo M.Chitin and chitosan preparation from marine sources.Structure,properties and application.Mar Drugs.2015;13(3):1133-1174.

[12] Rinaudo M,Le Dung P, Gey C, et al. Substituent distribution on O,N-carboxymethylchitosans by 1H and 13C n.m.r. Int J Bilo Macromol.1992;12:122.

[13] Muzzarelli RA, Tanfani F, Emanuelli M, et al.Sulfated N-(carboxymethyl)chitosans: novel blood anticoagulants. Carbohydr Res.1984;126(2):225-231.

[14] Park IK, Yang J, Jeong HJ, et al. Galactosylated chitosan as a synthetic extracellular matrix for hepatocytes attachment. Biomaterials. 2003;24(13):2331-2337.

[15] Khan TA, Peh KK, Ch'ng HS.Reporting degree of deacetylation values of chitosan: the influence of analytical methods.J Pharm Pharm Sci. 2002;5(3):205-212.

[16] Seyed YV, Motahareh E, Mohsen A,et al. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the in?amed intestinal mucosa. Carbohydrate Polymers. 2016;144: 371–381.

[17] Chang JE, Cho HJ, Yi E, et al. Hypocrellin B and paclitaxel-encapsulated hyaluronic acid–ceramide nanoparticles for targeted photodynamic therapy in lung cancer. J Photochem Photobiol B. 2016;158:113-121.

[18] Ramos-Torrecillas J, Garcia-Martinez O,Luna-Bertos ED,et al. Effectiveness of platelet-rich plasma and hyaluronic acid for the treatment and care of pressure ulcers. Biol Res Nurs. 2015;17 (2): 152-158.

[19] Dalmedico MM, Meier MJ, Felix JV, et al. Hyaluronic acid covers in burn treatment a systematic review. Rev Esc Enferm USP. 2016;50(3): 519-524.

[20] Choi YS, Hong SR, Lee YM, et al.Studies on gelatin-containing artificial skin: II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge.J Biomed Mater Res.1999;48(5):631-639.

[21] Duranti F, Salti G, Bovani B, et al. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998;24(12):1317-1325.

[22] Radomsky ML, Aufdemorte TB, Swain LD, et al. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates.J Orthop Res. 1999;17(4):607-614.

[23] Brow MB, Siligardi G,Karim S, et al//Fourth international workshop on hyaluroman in drug delivery, willough by , d., ed. RSM prss, London.1996:79.

[24] Yang B, Yang BL, Savani RC, et al.Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein.EMBO J. 1994;13(2): 286-296.

[25] 于飞,奚廷婓,张姝江,等. 具有垂直孔道的壳聚糖乳酸盐海绵的制备及体外释药模型的拟合分析[J]. 高等学校化学学报, 2012, 33(4):843-849.

[26] 李娜梅,杨飒,宁倩,等.半乳糖化壳聚糖—氟尿嘧啶偶合物纳米给药体系的制备、表征及体外性能研究[J].南华大学学报(自然科学版), 2015,29(3)：82-91.

[27] 顾秋忠，陆照林,翁辞海,等.透明质酸钠在腹盆腔手术中预防粘连的临床研究.中华全科医学[J].2015,13(4): 579-581.

[28] 朱香利.壳聚糖生物医用材料的应用[J].中外医疗, 2013,(14): 12-14.